Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular Lymphoma

Video

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Elizabeth Lihua Budde, MD, PhD, an assistant professor at City of Hope, discusses how a phase I/Ib clinical trial evaluating mosunetuzumab in patients with follicular lymphoma (FL) is different than other clinical trials.

Patients receive this novel treatment for a limited number of cycles, Budde says. Initial treatment is only 8 cycles, and the patient may remain in follow-up rather than being treated until progression or relapse.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content